WO2005000825A1 - チアゾールイミン類およびオキサゾールイミン類 - Google Patents
チアゾールイミン類およびオキサゾールイミン類 Download PDFInfo
- Publication number
- WO2005000825A1 WO2005000825A1 PCT/JP2004/009249 JP2004009249W WO2005000825A1 WO 2005000825 A1 WO2005000825 A1 WO 2005000825A1 JP 2004009249 W JP2004009249 W JP 2004009249W WO 2005000825 A1 WO2005000825 A1 WO 2005000825A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- substituted
- unsubstituted
- saturated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 258
- -1 oxazolimine compound Chemical class 0.000 title claims description 119
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 33
- 229940002612 prodrug Drugs 0.000 claims abstract description 33
- 239000000651 prodrug Substances 0.000 claims abstract description 33
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 31
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims abstract description 18
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 15
- 206010019280 Heart failures Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 claims abstract description 4
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 86
- 125000000623 heterocyclic group Chemical group 0.000 claims description 41
- 125000003367 polycyclic group Chemical group 0.000 claims description 30
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 125000004434 sulfur atom Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000003277 amino group Chemical group 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 206010020571 Hyperaldosteronism Diseases 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims description 4
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 4
- 206010039083 rhinitis Diseases 0.000 claims description 4
- 230000001953 sensory effect Effects 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 206010030043 Ocular hypertension Diseases 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 201000002282 venous insufficiency Diseases 0.000 claims description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 229940119334 Chymase inhibitor Drugs 0.000 claims description 2
- 239000003601 chymase inhibitor Substances 0.000 claims description 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 1
- 108090000227 Chymases Proteins 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052760 oxygen Chemical group 0.000 abstract description 4
- 239000001301 oxygen Chemical group 0.000 abstract description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 239000011593 sulfur Substances 0.000 abstract description 3
- 102000003858 Chymases Human genes 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 description 91
- 239000002904 solvent Substances 0.000 description 83
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 78
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 72
- 238000006243 chemical reaction Methods 0.000 description 71
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 238000003786 synthesis reaction Methods 0.000 description 64
- 230000015572 biosynthetic process Effects 0.000 description 62
- 230000014759 maintenance of location Effects 0.000 description 61
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 52
- 238000001308 synthesis method Methods 0.000 description 44
- 239000000243 solution Substances 0.000 description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 41
- 239000000203 mixture Substances 0.000 description 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 39
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- 230000002829 reductive effect Effects 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- 150000002430 hydrocarbons Chemical group 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 238000009835 boiling Methods 0.000 description 23
- 239000002585 base Substances 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 239000005711 Benzoic acid Substances 0.000 description 19
- 235000010233 benzoic acid Nutrition 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 17
- 239000002253 acid Substances 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- 102100024539 Chymase Human genes 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 125000006239 protecting group Chemical group 0.000 description 13
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000001704 evaporation Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000001841 imino group Chemical group [H]N=* 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 7
- 150000007980 azole derivatives Chemical class 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- 150000002540 isothiocyanates Chemical class 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 6
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- 150000008065 acid anhydrides Chemical class 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- XMWGTKZEDLCVIG-UHFFFAOYSA-N 1-(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1 XMWGTKZEDLCVIG-UHFFFAOYSA-N 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 4
- PVTXJGJDOHYFOX-UHFFFAOYSA-N 2h-1,4-benzoxazine Chemical compound C1=CC=C2N=CCOC2=C1 PVTXJGJDOHYFOX-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 102400000345 Angiotensin-2 Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229940095102 methyl benzoate Drugs 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 150000007978 oxazole derivatives Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ONJRTQUWKRDCTA-UHFFFAOYSA-N 2h-thiochromene Chemical compound C1=CC=C2C=CCSC2=C1 ONJRTQUWKRDCTA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000005138 alkoxysulfonyl group Chemical group 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000002140 halogenating effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- HUNUAFNLLYVTQD-UHFFFAOYSA-N methyl 2-chlorosulfonylbenzoate Chemical compound COC(=O)C1=CC=CC=C1S(Cl)(=O)=O HUNUAFNLLYVTQD-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 2
- ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical class NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- LWZYUACNWRVDDJ-UHFFFAOYSA-N 1-benzoxepine Chemical compound O1C=CC=CC2=CC=CC=C12 LWZYUACNWRVDDJ-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 description 2
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 2
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 2
- AMATXUCYHHHHHB-UHFFFAOYSA-N 5,5-dibromo-1,3-diazinane-2,4,6-trione Chemical compound BrC1(Br)C(=O)NC(=O)NC1=O AMATXUCYHHHHHB-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- WAKRDDXHAXBEQA-UHFFFAOYSA-N benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC=C1 WAKRDDXHAXBEQA-UHFFFAOYSA-N 0.000 description 2
- FBOSKQVOIHEWAX-UHFFFAOYSA-N benzothiazine Chemical compound C1=CC=C2N=CCSC2=C1 FBOSKQVOIHEWAX-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
- 229940116357 potassium thiocyanate Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- 150000007979 thiazole derivatives Chemical class 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- JZVATIQSUFESHS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,2,3-benzotriazine Chemical compound C1=CC=C2CNNNC2=C1 JZVATIQSUFESHS-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- PXPHCHJRHCHFGZ-UHFFFAOYSA-N 1,4-benzodiazocine Chemical compound N1=CC=NC=CC2=CC=CC=C21 PXPHCHJRHCHFGZ-UHFFFAOYSA-N 0.000 description 1
- IBJUOHSSKYWIIN-UHFFFAOYSA-N 1,4-benzoxathiine Chemical compound C1=CC=C2OC=CSC2=C1 IBJUOHSSKYWIIN-UHFFFAOYSA-N 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- LFHLEABTNIQIQO-UHFFFAOYSA-N 1H-isoindole Chemical compound C1=CC=C2CN=CC2=C1 LFHLEABTNIQIQO-UHFFFAOYSA-N 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- TVWWELUJVHZWDG-UHFFFAOYSA-N 2,2,2-trifluoro-n-(4-methyl-1,3-thiazol-2-yl)acetamide Chemical compound CC1=CSC(NC(=O)C(F)(F)F)=N1 TVWWELUJVHZWDG-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 description 1
- FOCKIYZLSZKVDH-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-imidazo[4,5-b]pyridine Chemical compound N1C=CC=C2NCNC21 FOCKIYZLSZKVDH-UHFFFAOYSA-N 0.000 description 1
- DALSOYJDNXEMSN-UHFFFAOYSA-N 2,3-dichlorofuran Chemical compound ClC=1C=COC=1Cl DALSOYJDNXEMSN-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- PWYJJQYPSILKKB-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate;hydrochloride Chemical compound Cl.C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 PWYJJQYPSILKKB-UHFFFAOYSA-N 0.000 description 1
- UPGZVLNSUYYGEQ-UHFFFAOYSA-N 2-[(2-amino-1,3-thiazol-5-yl)methyl]isoindole-1,3-dione Chemical compound S1C(N)=NC=C1CN1C(=O)C2=CC=CC=C2C1=O UPGZVLNSUYYGEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- LDSQQXKSEFZAPE-UHFFFAOYSA-N 2-piperidin-4-ylethanol Chemical compound OCCC1CCNCC1 LDSQQXKSEFZAPE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- QSBQHEHNHCBCAA-UHFFFAOYSA-N 3,4-dihydrooxathiine Chemical compound C1CC=COS1 QSBQHEHNHCBCAA-UHFFFAOYSA-N 0.000 description 1
- BCVAGKRCMVWXOQ-UHFFFAOYSA-N 3-azatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),9,11-hexaene Chemical compound C1=CC=CC2=CNC3=CC=CC1=C32 BCVAGKRCMVWXOQ-UHFFFAOYSA-N 0.000 description 1
- BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- HNOGSSUZDLBROJ-UHFFFAOYSA-N 5-ethyl-1,3-thiazol-2-amine Chemical compound CCC1=CN=C(N)S1 HNOGSSUZDLBROJ-UHFFFAOYSA-N 0.000 description 1
- ASAMCDOTLOUAAR-UHFFFAOYSA-N 5-ethyl-1,3-thiazole Chemical compound CCC1=CN=CS1 ASAMCDOTLOUAAR-UHFFFAOYSA-N 0.000 description 1
- GUABFMPMKJGSBQ-UHFFFAOYSA-N 5-methyl-1,3-thiazol-2-amine Chemical compound CC1=CN=C(N)S1 GUABFMPMKJGSBQ-UHFFFAOYSA-N 0.000 description 1
- DTRRHWQMEXXDFE-UHFFFAOYSA-N 8,9-dihydro-7h-benzo[7]annulene Chemical compound C1CCC=CC2=CC=CC=C21 DTRRHWQMEXXDFE-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- ZBJJDYGJCNTNTH-UHFFFAOYSA-N Betahistine mesilate Chemical group CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1 ZBJJDYGJCNTNTH-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000909983 Homo sapiens Chymase Proteins 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical compound C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- UTCMYCAFVUUNBK-UHFFFAOYSA-N benzo[cd]indole Chemical compound C1=CC(C=N2)=C3C2=CC=CC3=C1 UTCMYCAFVUUNBK-UHFFFAOYSA-N 0.000 description 1
- XSIFPSYPOVKYCO-UHFFFAOYSA-N benzoic acid butyl ester Natural products CCCCOC(=O)C1=CC=CC=C1 XSIFPSYPOVKYCO-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- JXHYCCGOZUGBFD-UHFFFAOYSA-N benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1 JXHYCCGOZUGBFD-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 229940047583 cetamide Drugs 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- OIOCAANXMDJBLU-UHFFFAOYSA-N cyclohepta[b]pyridine Chemical compound C1=C=CC=C2C=CC=NC2=C1 OIOCAANXMDJBLU-UHFFFAOYSA-N 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N ethyl ethylene Natural products CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- FATAVLOOLIRUNA-UHFFFAOYSA-N formylmethyl Chemical group [CH2]C=O FATAVLOOLIRUNA-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 108010089230 histamine-releasing peptide Proteins 0.000 description 1
- GCWCHLULHAWMEH-UHFFFAOYSA-N hydrazine;methanol;hydrate Chemical compound O.OC.NN GCWCHLULHAWMEH-UHFFFAOYSA-N 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- QKASDIPENBEWBU-UHFFFAOYSA-N methyl 2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1CBr QKASDIPENBEWBU-UHFFFAOYSA-N 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 150000008318 pyrimidones Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- NLWWBGRPAZGBPU-UHFFFAOYSA-N tert-butyl n-[2-(2-amino-1,3-thiazol-5-yl)ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCC1=CN=C(N)S1 NLWWBGRPAZGBPU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M tetrabutylammoniumhydrogensulfate Substances OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
Definitions
- the present invention relates to novel thiazole imines or oxazole imines, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- Chymase is one of the in vivo enzymes found in mast cell secretory granules and one of the subfamilies of chymotrypsin-like serine proteases. Chymase, when released extracellularly, rapidly binds to the surrounding extracellular matrix, cleaves the extracellular matrix of type IV collagen fibronectin, enhances vascular permeability with histamine, etc., and enhances histamine action. It produces histamine-releasing peptides from serum albumin, and also degrades IgG to a limited extent, forms leukocyte chemotactic factor, and activates the precursor of interleukin-10, one of the inflammatory cytokines. Has a body effect.
- ACE angiotensin-converting enzyme
- Chymase having such various physiological activities is known to be involved in various disease states, for example, myocardial infarction, heart failure, PTCA (Percutaneous Transluminal Coronary Angioplasty) is known to be involved in restenosis, hypertension, allergic diseases, organ fibrosis, etc.
- PTCA Percutaneous Transluminal Coronary Angioplasty
- an activity inhibitor for chymase is considered to be useful as a therapeutic agent for cardiovascular disorders, a therapeutic agent for arteriosclerosis, an anti-inflammatory agent, an anti-allergic agent and the like. More specifically, a compound having a chymase inhibitory action is used for a disease whose pathology is considered to be improved based on this action, for example, hypertension mediated by angiotensin II, endothelin, etc., heart failure, Ischemic peripheral circulatory disorder, myocardial ischemia, venous insufficiency, progression of heart failure after myocardial infarction, glycemic nephropathy, nephritis, arteriosclerosis, hyperaldosteronism, scleroderma, glomerulosclerosis, renal failure, CNS disease, Alzheimer's disease, memory deficiency, depression, sensory dysfunction including amnesia and senile dementia, anxiety and nervous symptoms, discomfort mental state, glaucoma, ocular hypertension, restenos
- Examples of the compound having a chymase inhibitory action include a benzimidazole derivative (see WO 00/03997 pamphlet), and a pyrimidone derivative (see WO 99/41927 pamphlet). And quinazolinone derivatives (see WO 00/10982 pamphlet). These compounds are structurally different from the compound of the present invention.
- thiazolimines and oxazolimines include, for example, compounds described in WO 02/02542 pamphlet and WO 92/15564 pamphlet.
- the compounds of the present invention are structurally different in that a substituent having a specific partial structure is present on the nitrogen atom of the imino group as shown in the formula (1). Disclosure of the invention
- An object of the present invention is to provide a compound having chymase inhibitory activity and useful as a therapeutic agent for the above-mentioned diseases.
- the present inventors have conducted intensive studies in order to achieve the above object, and as a result, have found that the compound represented by the general formula (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof (hereinafter referred to as the compound of the present invention as necessary) (May be abbreviated) has excellent chymase inhibitory activity. That is, the present invention relates to the following.
- X represents a sulfur atom or an oxygen atom.
- any one of two adjacent Carbon atoms can form double or triple bonds.
- Z is a saturated or unsaturated monocyclic hydrocarbon ring group, a saturated or unsaturated polycyclic hydrocarbon ring group, a saturated or unsaturated monocyclic heterocyclic group, a saturated or unsaturated polycyclic heterocyclic group
- M has the formula:.
- A is a saturated or unsaturated monocyclic hydrocarbon ring group, a saturated or unsaturated polycyclic hydrocarbon ring group, a saturated or unsaturated monocyclic heterocyclic group, or a saturated or unsaturated polycyclic group Represents a heterocyclic group (these groups may be unsubstituted or have a substituent).
- R 33 , R 34 , and R 35 are the same or different, and when there are a plurality of them, each independently represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted Or unsubstituted cycloalkyl group, substituted or unsubstituted
- R 2 2 and R 2 3, and R 3 2 and R 3 3 is, terrorist others into the connexion in the ring such together with the nitrogen atom to which they are attached are combined binding together It may also represent a saturated 3- to 8-membered cyclic amino group which may contain an atom (the cyclic amino group may be unsubstituted or may have a substituent).
- R 2 4 and R 3 5 is therewith when the oxygen atom number n of the sulfur atom attached is 1 or 2, have name a hydrogen atom.
- n 0, 1, or 2 each independently when there is more than one.
- n 0, 1, or 2 each independently when there is more than one.
- R 2 is a hydroxyl group, Shiano group, a halogen atom or an unsubstituted C _ 6 Al kill group, as a compound or its Purodora' grayed or pharmaceutical according to any one of [1] to [6] Acceptable salt.
- [8] The compound according to any one of [1] to [7], wherein A is a 1-naphthyl group or a 2-naphthyl group, a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- Z is a saturated or unsaturated monocyclic hydrocarbon ring group, a saturated or unsaturated polycyclic hydrocarbon ring group, saturated or heteromonocyclic group unsaturated or saturated or polycyclic heterocyclic group derconnection unsaturated, these groups has the formula: a Y 4 - is substituted with a group represented by Z ', [ 1] The compound according to any of [8] or a prodrug thereof or a pharmaceutically acceptable salt thereof.
- Z ' is a saturated or unsaturated monocyclic hydrocarbon ring group, a saturated or unsaturated polycyclic hydrocarbon ring group, a saturated or unsaturated monocyclic heterocyclic group, or a saturated or unsaturated polycyclic group Heterocyclic group (these groups are unsubstituted or one or more of the same or different groups selected from a halogen atom, a nitro group, a cyano group, an alkyl group, an aralkyl group, an alkoxy group, and an alkylenedioxy group; Which may be substituted)
- R 11 and n independently represent the same meaning as described above when there are a plurality.
- p and q represent an integer such that p + q is 0 to 6, and when p is 2 or more, one (CH 2 ) p — represents a double bond or a triple bond between adjacent carbon atoms. When q is 2 or more, one (CH 2 ) q — may form a double bond or a triple bond between adjacent carbon atoms,
- R 12 represents a substituted or unsubstituted benzene ring or a substituted or unsubstituted cycloalkane ring;
- a medicament comprising the compound according to any one of [1] to [10], a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- a chymase inhibitor comprising the compound according to any one of [1] to [10], a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- Various groups in the present invention will be described below. Unless otherwise indicated, the following description also applies to the case where each group is a part of another group.
- the radicals are each a saturated or unsaturated monocyclic hydrocarbon ring, a saturated or unsaturated polycyclic hydrocarbon ring, a saturated or unsaturated monocyclic heterocycle, and a saturated or unsaturated It means that one hydrogen atom of a saturated polycyclic heterocycle is changed to a bond.
- saturated or unsaturated monocyclic hydrocarbon ring examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclohexane, cyclopentene, cyclopentene, cyclohexene, cyclohepten, and cyclopent Examples include 3- to 8-membered hydrocarbon rings such as octene and benzene.
- saturated or unsaturated polycyclic hydrocarbon ring examples include, for example, indene, naphthalene, azulene, phenolene, phenalene, phenanthrene, anthracene, acephenanthrylene, 1,2-dihydronaphthalene, 6,7-dihydro 5H-Benzocycloheptene, benzocyclootane, 1,2,3,4-tetrahydronaphthalene, decahydronaphthalene, octahydro-1H-indene, etc., polycyclic hydrocarbon ring with 16 or less carbon atoms Adamantan, bicyclo [2,2,2:] octane, bicyclo [3,3,3] ndecane, bicyclo [2,2,2] otatan 2-ene, bicyclo [3,3,3] ] Ende force—A polycyclic hydrocarbon ring having 12 or less carbon atoms and having a bridge such as 2-ene.
- saturated or unsaturated monocyclic heterocyclic ring examples include, for example, a 3- to 8-membered unsaturated monocyclic heterocyclic ring having 1 to 4 nitrogen atoms, and a 3 to 4 nitrogen-containing heterocyclic ring.
- Examples of the 3- to 8-membered unsaturated monocyclic heterocyclic ring containing 1 to 4 nitrogen atoms include, for example, pyrroline, pyrroline, pyridine, dihydropyridine, imidazonore, pyrazonole, imidazoline, pyrazine, pyrimidine, pyridazine, Pyrazonole, triazonole, tetrazole and the like.
- Examples of the 3- to 8-membered saturated monocyclic heterocyclic ring containing 1 to 4 nitrogen atoms include, for example, piperidine, piperidine, imidazolidine, virazolidine, piperazine and the like.
- Examples of the 3- to 8-membered unsaturated monocyclic heterocyclic ring containing one oxygen atom include furan and pyran.
- Examples of the 3- to 8-membered unsaturated monocyclic heterocyclic ring containing 1 to 2 sulfur atoms include thiophene, dihydrodithioin, and dihydrodithione.
- oxazole As a 3- to 8-membered unsaturated monocyclic heterocycle containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms, for example, oxazole, oxadiazole, isoxazole and the like can be mentioned.
- Examples of the 3- to 8-membered saturated monocyclic complex containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms include morpholine and oxazolidin.
- Examples of the 3- to 8-membered unsaturated monocyclic heterocyclic ring containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms include thiazole, isotiazole and thiadiazole.
- Examples of the 3- to 8-membered saturated monocyclic complex containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms include thiazolidine.
- saturated or unsaturated polycyclic heterocyclic ring for example, a saturated or unsaturated condensed heterocyclic ring containing 1 to 4 nitrogen atoms, containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms Unsaturated condensed heterocycle containing 1-3 nitrogen atoms and 1-2 sulfur atoms Unsaturated condensed heterocycle containing 1-2 oxygen atoms, 1 oxygen Unsaturated condensed heterocycles containing an atom and 1-2 sulfur atoms, and unsaturated condensed heterocycles containing 1-2 sulfur atoms are included.
- indole isoindole, indoline, quinoline, isoquinoline, quinolizine, indazono, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, carbazole , Purine, pteridine, phenazine, carbolinine, phenanthridine, ataridine, indoline, isoindoline, 1,2-dihydroisoquinoline, benzimidazole, imidazopyridine, benzotriazole, tetrahydroimidazopyridine, benz [b] azepine, benz [cd] indole, cyclohepta [cd] indole, pyro-mouth [3, 2, 1— ij] quinoline, cyclohexa [ 0
- Examples of the unsaturated condensed heterocyclic ring containing 1 to 3 nitrogen atoms and 1 to 2 oxygen atoms include, for example, benzoxazonole, benzoxadiazonole, phenoxazine, and pyrrole [1, 2, 3—de] [1, 4] Benzoxazine, Piro mouth [2, 1—c] [1, 4] Benzoxazine, Piro mouth [3, 2, 11 k 1] Benz [e] [4, 1]
- Oxazosin Preferred are benzoxazole, pyro mouth [1,2,3-de] [1,4] benzoxazine, pyro mouth [2,11c] [1,4] benzoxazine, pyro mouth [3, 2, 1-1 kl] benz [e] [4, 1] oxazosin.
- Examples of the unsaturated condensed heterocyclic ring containing 1 to 3 nitrogen atoms and 1 to 2 sulfur atoms include benzothiazolone, benzothiadiazo 1 / re, 1,4-benzothiazine and phenothiazine. Preferred are benzothiazole and 1,4-benzothiazine.
- Examples of the unsaturated condensed heterocyclic ring containing one or two oxygen atoms include benzofuran, dihydrobenzofuran, chromene, isobenzofuran, xanthene, isochroman, chroman, benz [b] oxepin, and preferably benzofuran. , Benz [b] oxepin and the like.
- Examples of the unsaturated condensed heterocyclic ring containing one oxygen atom and one or two sulfur atoms include 1,4-benzoxathiin and phenoxathiin.
- Examples of the unsaturated condensed heterocyclic ring containing one or two sulfur atoms include benzothiophene, benzothiin, benzothiopyran, thiochroman, and thianthrene, and preferably benzothiophene, benzothiopyran, and thiochroman.
- a 5- to 6-membered aromatic heterocycle formed together by Q and a C C group to which it is attached, ie, having the formula:
- the partial structure represented by is a 5- to 6-membered aromatic heterocyclic ring containing 1 to 2 nitrogen atoms, 0 to 1 oxygen atom, and / or 0 to 1 sulfur atom, adjacent to Group in which a hydrogen atom on a carbon atom is replaced by a bond. More specifically, a group in which a hydrogen atom on an adjacent carbon atom of pyridine, pyrazine, pyridazine, pyrimidine, pyrrole, imidazole, pyrazole, thiophene, thiazonole, isothiazonole, furan, oxazonole, or isoxazole is changed to a bond. No.
- benzene ring or 5- to 6-membered aromatic heterocyclic ring is represented by the following formula:
- Examples of the alkyl group include a lower alkyl group.
- Examples of the lower alkyl group include methinole, ethynole, propinole, 2-propyl, pentinole, 2-petinole, 2-methinolepropynole, 1,1-dimethinoletinole, pentinole, and Examples include straight-chain or branched alkyl groups having 6 or less carbon atoms, such as xinole, heptinole, and cytinole.
- cycloalkyl group examples include 3- to 8-membered cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and 2-hexylhexyl.
- alkenyl group examples include a lower alkenyl group, and examples of the lower alkenyl group include straight-chain or branched alkenyl groups such as butyl, aryl, propyl, 2-propenyl, butyr, pentenyl, and hexenyl. Examples thereof include a branched alkenyl group having 6 or less carbon atoms.
- alkynyl group examples include lower alkynyl groups.
- examples of the lower alkynyl group include straight-chain or branched alkynyl groups having 6 or less carbon atoms such as ethynyl, propargyl, butynyl, and pentynyl.
- alkoxy group examples include a group in which an oxygen atom is bonded to a bond of the alkyl group.
- alkylenedioxy group examples include groups in which an oxygen atom is bonded to both of the two bonds of the alkylene group.
- halogen atom examples include iodine, fluorine, chlorine, and bromine atoms.
- acryl group examples include a formyl group, for example, an alkanol group having 2 to 6 carbon atoms such as acetyl and propanol, and a carbon atom such as cyclopropanecarbol, cyclobutanecarbol, cyclopentanecaprolponyl and cyclohexanecarbonyl.
- a formyl group for example, an alkanol group having 2 to 6 carbon atoms such as acetyl and propanol
- a carbon atom such as cyclopropanecarbol, cyclobutanecarbol, cyclopentanecaprolponyl and cyclohexanecarbonyl.
- the aralkyl group include a heteroaromatic asinole group having a 5- or 6-membered heteroaromatic ring containing one or two heteroatoms selected from nitrogen, oxygen, and sulfur such as kochinol and isonicotinoy
- alkylene group examples include a lower alkylene group.
- the lower alkylene group examples include a straight-chain or branched alkylene group having 6 or less carbon atoms such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, and ethylethylene. Is mentioned.
- the benzene ring which can be replaced by one CH 2 — group of an alkylene group in Y 1 , Y 2 , Y 3 , Y 4, etc. includes o—, m—, or p-phenylene.
- Examples of the roanolecan ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, and the like in which two hydrogen atoms of a 3- to 8-membered cycloacan ring are replaced by a bond.
- the alkyl group, the alkyl group, the alkyl group, the alkanol group, the alkyl moiety of the aralkyl group and the alkylene group may have one or more substituents, which may be the same or different.
- R 6 1, R 6 2 , R 6 3, R 6 4, R 6 5, and R 6 6 are the same or different, a hydrogen atom, an alkyl group, a cycloalkyl represents a group or Ararukiru group,
- R 6 4 is an oxygen atom number n on the sulfur atom attached with it not the case a hydrogen atom of 1 or 2.
- R 6 2 and R 6 3 are bonded to each other cyclic Amino group for the nitrogen atom with connexion ring others may saturated 3-8 membered also contain heteroatoms in the ring, such together to which they are attached Can also be represented.
- a saturated or unsaturated monocyclic hydrocarbon ring, a saturated or unsaturated polycyclic hydrocarbon ring, a saturated or unsaturated monocyclic heterocyclic ring, and a saturated or unsaturated polycyclic heterocyclic ring, a phenyl group, Benzene represented by an arylo group, a saturated heterocyclic monocarbonyl group, a heteroaromatic acyl group, an aryl moiety of a substituted aralkyl group, and a group represented by Q and its bonding formula: 1 C C—
- the substituents on the ring and the 5- or 6-membered aromatic heterocyclic ring may be one or more, and may be the same or different.For example, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted group Alkynyl, substituted or unsubstituted cycloalkyl, alkylenedi
- R 5 1, R 5 2 , R 5 3, R 5 4, R 5 5, and R 5 6 are the same even in properly or different, a hydrogen atom, an alkyl group, cycloalkyl group or a Ararukiru group table but,, R 5 4 is an oxygen atom number n on the sulfur atom attached with it not the case a hydrogen atom of 1 or 2.
- R 5 2 and R 5 3 is bonded to each other cyclic amino of nitrogen atom with connexion ring others to may contain a hetero atom saturated 3-8 membered in the ring such together to bind It can also represent a group.
- R 2 2 and R 2 3, R 3 2 and R 3 3, R 5 2 and R 5 3 or R 6 2 and R 6 3 is attached to the doctor each other, to form together with the nitrogen atom to which they are attached
- the hetero atom of the saturated 3- to 8-membered cyclic amino group which may contain another hetero atom in the ring includes an oxygen atom, a nitrogen atom, and a sulfur atom.
- Specific examples of such a saturated 3- to 8-membered cyclic amino group include a 3- to 8-membered ring group containing 1 to 3 nitrogen atoms or a 3- to 8-membered ring group containing 1 nitrogen atom and 1 oxygen atom.
- cyclic groups such as 1-piperidinyl, 1-piperidino, 1-piperazinyl, morpholino, and 11- (4-methyl) piperazinyl.
- substituent for the saturated 3- to 8-membered cyclic amino group cycloalkyl group, cycloalkane ring, cycloalkanecarbonyl group, and cycloalkenecarbonyl group
- the same groups as the substituents for the alkyl group and the above-mentioned substituted alkyl group can be used. Is mentioned.
- the compounds of the present invention include those having an optically asymmetric center, and therefore, they can be obtained as a racemate or in an optically active form when an optically active starting material is used. If necessary, the racemates obtained can be physically or chemically resolved into their optical antipodes by known methods. Preferably, diastereomers are formed from the racemate by reaction with an optically active resolving agent. Diastereomers can be separated by a known method such as fractional crystallization.
- the “prodrug” includes one that is easily hydrolyzed in a living body and regenerates the compound represented by the formula (1).
- the carboxyl group is substituted with an alkoxycarbonyl group.
- Natsume compound, alkyl thiocar A compound that has become a ponyl group or a compound that has become an alkylaminocarbonyl group can be given.
- a compound having an amino group a compound in which the amino group is substituted with an alkanoyl group to form an alkanolamino group, a compound in which the amino group is substituted with an alkoxycarbonyl group to form an alkoxycarbamino group, acyloxymethyl
- the compound include an amino group and a hydroxylamine compound.
- a compound in which the hydroxyl group has been replaced with the above-mentioned acyl group to be an acyloxy group a compound which has become a phosphoric ester, or a compound which has become an acyloxymethyloxy group can be mentioned. .
- a compound having a sulfo group a compound in which the sulfo group is substituted with an alkyl group to form a sulfonic acid ester may be mentioned.
- alkyl portion of the group used in these prodrugs examples include the aforementioned alkyl groups, and the alkyl group may be substituted (for example, with an alkoxy group having 1 to 6 carbon atoms).
- Preferred examples include the following.
- Examples of a compound in which a carboxyl group is an alkoxycarbonyl group include, for example, methoxycarbonyl, ethoxycanolepole, and other anorecoxycanololepol (for example, lower alkoxycarbonyl having 1 to 6 carbon atoms, etc.). ), Alkoxycarbonyl substituted by an alkoxy group such as methoxymethoxycarbonyl, ethoxymethoxycarbonyl, 2-methoxyethoxycarbonyl, 21-methoxyethoxymethoxycarbonyl, pivaloyloxymethoxycarbonyl (for example, having 1 to 6 carbon atoms, etc.) Lower alkoxyl propyl).
- Examples of a compound in which a sulfo group is an alkoxysulfonyl group include anorecoxisinolehoninole such as methoxysinolephoninole and ethoxysinolephoninole (for example, a compound having 1 to 6 carbon atoms).
- Lower alkoxysulfonyl groups such as lower alkoxysulfonyl), methoxymethoxysulfonyl, ethoxymethoxytoxinolephoninole, 2-methoxytoxin / lephoninole, 2-methoxyethoxytoxinolephoninole, and piperoyloxymethoxytoxinolephoninole
- lower alkoxy sulfol having 1 to 6 carbon atoms and the like can be mentioned.
- the compound represented by the formula (1) or a prodrug thereof can be converted into a pharmaceutically acceptable salt, if necessary.
- Such salts include, for example, hydrochloric acid, bromide Salts with mineral acids such as hydrogen acid, sulfuric acid and phosphoric acid; salts with organic canoleponic acids such as formic acid, acetic acid, fumaric acid, maleic acid, oxalic acid, citric acid, malic acid, tartaric acid, aspartic acid and glutamic acid; Salts with sulfonic acids such as methanesulfonic acid, benzenes / lephonic acid, p-tonolenesnolefonic acid, hydroxybenzenesnolefonic acid, dihydroxybenzenesnolefonic acid; and
- alkaline metal salts such as sodium salt and potassium salt
- alkaline earth metal salts such as calcium salt and magnesium salt
- ammonium salt triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, dicyclohexylamine salt.
- N, N, and a salt with dibenzylethylenediamine are examples of alkaline metal salts such as sodium salt and potassium salt
- alkaline earth metal salts such as calcium salt and magnesium salt
- ammonium salt such as sodium salt and potassium salt
- alkaline earth metal salts such as calcium salt and magnesium salt
- ammonium salt triethylamine salt
- pyridine salt pyridine salt
- picoline salt ethanolamine salt
- dicyclohexylamine salt dicyclohexylamine salt.
- the compound represented by the formula (1) or a prodrug thereof or a pharmaceutically acceptable salt thereof may be an anhydride, hydrate or solvate thereof.
- the compounds of the present invention can be administered orally or parenterally when using them as medicaments. That is, it can be administered orally in a commonly used dosage form such as powder, granules, tablets, capsules, syrups, suspensions, etc., or, for example, in the form of a solution,? Parenteral administration can be made in the form of injections in the form of L preparations and suspensions. It can also be administered rectally in the form of suppositories.
- suitable dosage form can be produced, for example, by mixing the compound of the present invention with an acceptable usual carrier, excipient, binder, stabilizer, or diluent.
- an acceptable buffer, solubilizing agent, or isotonic agent can be added. Dosage and frequency vary depending on, for example, target disease, symptoms, age, body weight, and dosage form
- 0.1 to 2000 mg, preferably 1 to 200 mg per day can be administered to an adult in one or several divided doses (for example, 2 to 4 doses).
- the compound represented by the formula (1) can be synthesized from a known compound by combining known synthesis methods, and for example, can be synthesized by the following method. Synthesis method (A)
- the compound of the present invention can be generally synthesized by the following method.
- L represents a halogen atom such as a chlorine atom or a bromine atom, or a methanesulfonyloxy group or the like.
- a compound represented by the formula (2) and a compound represented by the formula (3) are mixed with a base in a solvent inert to the reaction (for example, N, N-dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, dichloromethane, etc.).
- a base inert for example, N, N-dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, dichloromethane, etc.
- the compound represented by the formula (1) can be produced by reacting at 0 ° C. to the boiling point of the solvent in the presence of
- Examples of the base used in the above reaction include the following.
- an inorganic base eg, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, etc.
- an organic base eg, triethylamine, pyridine, etc.
- an alkali metal hydride eg, potassium hydride, Sodium hydride
- iodide salts such as n-tetrabutylammonium iodide, sodium iodide and potassium iodide, or 4_ (N, N-dimethylamino) pyridine Etc.
- phase transfer catalyst eg, n-tetrabutylammonium hydrogen sulfate, n-tetrabutylammonium bromide, etc.
- a represents a part of Y 2 other than a part specified by a specific group such as one CO— in this case) can be produced, for example, by the following synthesis method.
- the compound represented by the formula (la) By reacting the compound represented by the formula (2) with a carboxylic acid represented by the formula (3a) in the presence of a condensing agent in an inert solvent at room temperature or under heating, the compound represented by the formula (la) is obtained.
- the compounds represented can be prepared.
- a compound represented by the formula (2) and an acid halide or an acid anhydride of the carboxylic acid represented by the formula (3a) are mixed in an inert solvent at 0 ° C. It can also be carried out by reacting at the boiling point.
- Examples of the condensing agent used in the above reaction include the following.
- the following are similarly exemplified. That is, for example, dicyclohexyl carpoimide (DCC), disopropyl carpoimide (DIPC), 1-ethyl-3- (3-dimethylaminopropyl) carboximide (WSC), benzotriazole-11 Yl-tris (dimethylamino) phosphonium 'hexafluorophosphoride (BOP), diphenylphosphonyldiamid (DPPA), N, N-carbonyldiimidazole (Angew. Chem. Int. Ed.
- the solvent examples include aromatic hydrocarbon solvents such as benzene, tonolene, and xylene; ether solvents such as tetrahydrofuran and 1,4-dioxane; and halogenated hydrocarbons such as dichloromethane, chloroform, and 1,2-dichloroethane.
- examples thereof include hydrogen solvents, amide solvents such as dimethylformamide and dimethylacetamide, basic solvents such as pyridine, and mixed solvents thereof.
- the base examples include inorganic bases such as sodium hydroxide, sodium hydroxide, sodium carbonate, sodium carbonate, and organic bases such as triethylamine and pyridine. Acid chlorides or acid bromides can be mentioned as the acid nodronide.
- the acid anhydride a mixed acid anhydride obtained by reaction with an alkyl chloroformate or the like can be used. Synthesis method (C)
- Y 2 in the formula (1) has the formula:
- a CO- NH- Y 2 a - compound represented by (lb) (Y 2 3 Out of Y 2, specific to one CO- NH- in this case Represents a portion other than the portion specified by the group), for example, can be produced by the following synthesis method.
- a compound represented by the formula (2) and a compound represented by the formula (3b) or (3b ') are reacted with a solvent inert to the reaction (for example, N, N-dimethylformamide, dimethylsulfoxide).
- the compound represented by the formula (lb) is produced by reacting in the presence or absence of a base at 0 ° C to the boiling point of the solvent in a solvent such as side, tetrahydrofuran, or dichloromethane. Can be built.
- Y 2 in the formula (1) has the formula: over S_ ⁇ 2 -NH-Y 2 a - compound represented by (1 c) (Y 2 a is of Y 2, in this case one S0 2 - NH- of Represents a portion other than the portion specified by a specific group as described above), for example, can be produced by the following synthesis method (D1) or (D2).
- a compound represented by the formula (Ic) is converted to an alcohol represented by the formula (3c ′) in an inert solvent at room temperature or under heating, for example, in the presence of getyl azodicarboxylate and triphenylphosphine. By reacting, the compound represented by the formula (lc) can be produced.
- an amine derivative represented by the formula (6) and a compound represented by the formula (7) are used.
- the compound represented by the formula (8) can be produced by reacting the resulting compound at a temperature of from 178 ° C to room temperature in the presence or absence of a base. Further, the resulting compound represented by the formula (8) and the compound represented by the formula (2) are reacted in a solvent inert to the reaction in the presence of a base at 0 ° C to the boiling point of the solvent. , The formula (Id) Can be produced.
- the compound represented by the formula (2) used in the above synthesis method (to (D) can be synthesized from a known compound by combining known synthesis methods, and for example, can be synthesized by the following method. ⁇
- the azole derivative represented by the formula (9) is converted to the compound represented by the formula (2) according to the method described in a literature (eg, Biog. Med. Chem., 1996, 6, 1469.).
- the resulting compound can be produced. That is, for example, in an inert solvent (eg, toluene, tetrahydrofuran, dichloromethane, N, N-dimethylformamide, etc.), the azole derivative represented by the formula (9) and trifluoroacetic anhydride are converted into a salt. By reacting at 0 ° C.
- the compound represented by the formula (10) can be produced.
- the obtained compound represented by the formula (10) and the compound represented by the formula: L—Y 1 —A are reacted in a solvent inert to the reaction in the presence of a base at 0 ° C. to the boiling point of the solvent.
- the compound represented by the formula (11) can be produced.
- alkali hydrolysis using a hydroxide salt for example, sodium hydroxide or potassium hydroxide
- an alcoholic solvent for example, methanol or ethanol
- the compound represented by the formula (1) is obtained by converting the compound represented by the formula (9) It can also be produced without passing through the compound represented by (2).
- the following synthesis methods (F) and (G) can be mentioned.
- the azole derivative represented by the formula (9) and the compound represented by the formula (3) are converted into a solvent inert to the reaction (for example, N, N-dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, dichloromethane, etc.)
- a solvent inert to the reaction for example, N, N-dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, dichloromethane, etc.
- a compound in which Y 2 in the formula (1) is represented by the formula: one CO—Y 2 a 1 (la) (Y 2 a is specified by a specific group such as one CO— in Y 2 in this case) can be produced by, for example, the following synthesis method.
- the compound represented by 12a) By reacting the azole derivative represented by the formula (9) with a carboxylic acid represented by the formula (3a) in the presence of a condensing agent in an inert solvent at room temperature or under heating conditions, The compound represented by 12a) can be produced.
- an azole derivative represented by the formula (9) and an acid halide or acid anhydride of the carboxylic acid represented by the formula (3a) are added to an inert solvent at 0 ° C. It can be carried out by reacting at the boiling point of the solvent.
- the obtained compound represented by the formula (12a) and the compound represented by the formula: L—Y 1 —A are reacted in a solvent inert to the reaction in the presence of a base at 0 ° C. to the boiling point of the solvent.
- the compound represented by the formula (la) By reacting, the compound represented by the formula (la) can be produced.
- the starting compound used in the above synthesis method can also be produced by reacting a compound having a side chain bonded to form a thiazole ring or an oxazole ring.
- the following method can be used.
- the thiazole derivative (9A) in which X in the azole derivative represented by the formula (9) is represented by the formula: 1S— is synthesized by combining known synthesis methods from a known compound. For example, it can be synthesized by the following method.
- I 1 , R 2 and L have the same meanings as described above, and B represents a hydrogen atom or a protecting group such as tert-butoxycarbonyl-triphenylmethyl.
- the compound represented by the formula (15) can be produced by the following step (HI) or (H2).
- a compound represented by the formula (14) and a sulfonylating agent such as methanesulfonyl chloride are added to a reaction-inactive solvent (eg, methylene chloride, tetrahydrofuran, toluene, acetonitrile, etc.) in the presence of a base.
- a reaction-inactive solvent eg, methylene chloride, tetrahydrofuran, toluene, acetonitrile, etc.
- the compound represented by the formula (15) can be produced by reacting at 0 ° C. to the boiling point of the solvent in the absence.
- halogenating agent used in the step (HI) examples include bromine, iodine, pyridium bromide purbamide, and 5,5-dibromobarbituric acid.
- the compound represented by the formula (18) can be produced by the following step (J) or (J12).
- An isothiocyanate derivative represented by the formula (17) and a compound represented by the formula: NH 2 —Y 1 —A are reacted with a solvent inert to the reaction (for example, N, N-dimethylformamide, acetonitrile, tetrahydrofuran). , Dichloromethane, etc.) in the presence or absence of a base at 0 ° C. to the boiling point of the solvent to produce the thioperia derivative represented by the formula (18).
- a solvent inert to the reaction for example, N, N-dimethylformamide, acetonitrile, tetrahydrofuran). , Dichloromethane, etc.
- a compound represented by the formula: L 1 Y 1 —A and a thiocyanate are reacted with a solvent inert to the reaction (eg, acetonitrile, tetrahydrofuran, dichlorofuran).
- a solvent inert eg, acetonitrile, tetrahydrofuran, dichlorofuran.
- the isothiocyanate derivative represented by the formula (19) can be produced by reacting in methane or acetic acid) in the presence or absence of a base at 0 D C to the boiling point of the solvent.
- the obtained isothiocyanate derivative represented by the formula (19) and the compound represented by the formula: B—NH 2 are reacted with a solvent inert to the reaction (for example, acetoethryl, tetrahydrofuran, or dichloromethane).
- a solvent inert for example, acetoethryl, tetrahydrofuran, or dichloromethane.
- the obtained compound represented by the formula (18) and the compound represented by the formula (15) are converted into a compound (for example, J. Med, Chem., 1987, 30, 494. or Synth. Co. mm u n., 2002, 32, 1671.), and reacted under the same conditions as in the method for synthesizing the compound represented by the formula (9A).
- the group represented is a protecting group
- the compound represented by the formula (2A) can be produced by performing a deprotection reaction.
- R 1 R 2 , Y 2 , L, Q, M and B represent the same meaning as described above.
- the compound represented by the formula (21) can be produced by the following steps (J21), (J22) or (J23).
- the amine derivative represented by the formula (6) and thiophosgene are reacted in a solvent inert to the reaction (for example, acetonitrile, tetrahydrofuran, dichloromethane, etc.) in the presence or absence of a base at 0 ° C to the boiling point of the solvent.
- a solvent inert for example, acetonitrile, tetrahydrofuran, dichloromethane, etc.
- a base at 0 ° C to the boiling point of the solvent.
- the thioperia derivative represented by (21) can be produced.
- the compound represented by the formula (3) is reacted with a thiocyanate (for example, potassium thiocyanate, sodium thiocyanate, or ammonium thiocyanate) in the same manner as in the step (J12) of the above-mentioned synthesis method (J1).
- a thiocyanate for example, potassium thiocyanate, sodium thiocyanate, or ammonium thiocyanate
- the isothiocyanate derivative represented by the formula (20) can be produced.
- the obtained isothiocyanate derivative represented by the formula (20) and ammonia were subjected to the above-mentioned step (J21).
- a thioperia derivative represented by the formula (21) can be produced.
- the compound represented by the formula (6) and the compound represented by the formula (17) are reacted in the same manner as in the step (J11) of the above-mentioned synthesis method (J1), and then represented by B in the formula.
- the group to be protected is a protecting group
- the compound represented by the formula (21) can be produced by performing a deprotection reaction.
- R 1 R 2 , Y 1 , Y 2 , L, Q, A, and M represent the same meaning as described above, and the compound represented by the formula (22) can be prepared by the following step (J31) or (J32).
- the compound represented by the formula (20) 22 By reacting the compound represented by the formula (20) with the compound represented by the formula: NH 2 —Y 1- A in the same manner as in the step (J 12) of the above-mentioned synthesis method (J 1), the compound represented by the formula (20) 22) can be produced.
- the compound represented by the formula (19) and the compound represented by the formula (7) are synthesized by the above-mentioned synthesis method (J
- a thioperia derivative represented by formula (22) can be produced.
- the compound represented by the formula (22) and the compound represented by the formula (15) in the same manner as in the above-mentioned synthesis method (J1) or (J2) the compound represented by the formula (1A)
- the compounds represented can be prepared.
- the oxazole derivative (9B) wherein X is represented by the formula: 10- is a known compound.
- it can be synthesized by the following method (K1) or (K2).
- RR 2 and L represent the same meaning as described above, and E represents an alkoxy group such as a NH 2 group, a NHHP group, or an ethoxy group.
- the compound represented by the formula (25) can be produced by the following step (Kl 1) or (K12).
- the compound represented by the formula (23) can be synthesized according to the method for synthesizing the compound represented by the formula (9A) (step (HI) of the synthesis method (H)). That is, the compound represented by the formula (25) is obtained by reacting a solvent inert to the reaction, the compound represented by the formula (23), with a halogenating agent such as bromine or iodine at 0 ° C to the boiling point of the solvent. Manufacturing compounds Can.
- the compound represented by the formula (24) can be synthesized from the compound represented by the formula (9A) according to the method for synthesizing the compound represented by the formula (9A) (step (H2) of the synthesis method (H)). That is, the compound represented by the formula (24) is reacted with a sulfolating agent such as methanesulfonyl chloride in a solvent inert to the reaction in the presence or absence of a base at 0 ° C to the boiling point of the solvent. By reacting, the compound represented by the formula (25) can be produced.
- a sulfolating agent such as methanesulfonyl chloride
- the 2-aminoxazole derivative represented by the formula (9B) can be obtained by converting the compound represented by the formula (25) according to the method described in a literature (eg, Chem. Ber., 1966, 99, 21 10.). ) Can be synthesized. That is, a compound represented by the formula (25) and a compound represented by the formula (26) are mixed in a mixed solvent of an alcoholic solvent (eg, methanol, ethanol, 2-propanol, etc.) and water in the presence of sodium acetate. By reacting at room temperature to the boiling point of the solvent, the compound represented by the formula (9B) can be produced.
- an alcoholic solvent eg, methanol, ethanol, 2-propanol, etc.
- RR 2 and L represent the same meaning as described above, and X 1 represents an oxygen atom or a sulfur atom.
- B 1 represents a protecting group such as triphenylmethyl.
- the compound can be synthesized via a compound represented by the formula (27). That is, in a solvent inert to the reaction (eg, N, N-dimethylformamide, acetone, acetonitrile, tetrahydrofuran, etc.), an azide salt (eg, sodium azide, etc.) is added to the compound represented by the formula (25). Is reacted at 0 ° C. to the boiling point of the solvent to obtain a solvent represented by the formula (27).
- a solvent inert to the reaction eg, N, N-dimethylformamide, acetone, acetonitrile, tetrahydrofuran, etc.
- an azide salt eg, sodium azide, etc.
- the oxazole derivative (12B) in which X is represented by the formula: 1 O— can be obtained by combining a known synthesis method from a known compound. It can be synthesized, for example, by the following method.
- LC / MS conditions were as follows, and all analyzes were performed using this method.
- the distribution of mobile phases A and B at each time is as follows.
- Trifluoroacetic anhydride (6.18 ml, 43.8 mmo 1) was added to a solution of 2 _amino-5-methylthiazonole (5.OO g, 43.8 mmol) in tonoleene (150 ml) at 0 ° C. The mixture was added dropwise and stirred for 2 hours. After the reaction, saturated saline was added, and the mixture was extracted with chloroform. The organic layer was washed with 2M aqueous hydrochloric acid, saturated saline, saturated aqueous sodium hydrogen carbonate, and saturated saline in this order, and then dried over anhydrous sodium sulfate.
- Bromine (1.71 ml, 33.3 mmo 1) was added dropwise to a acetic acid solution (30 ml) of butyl aldehyde (2.40 g, 33.3 mmo 1) at room temperature.
- thioprea (2.78 g, 36.6 mmol) was added to the reaction solution, and the mixture was further refluxed for 2 hours.
- the precipitate was filtered and the solvent of the filtrate was distilled off under reduced pressure. After the obtained residue was dissolved in chloroform, it was washed with a saturated aqueous solution of sodium hydrogencarbonate and a saturated saline solution, and then dried over anhydrous sodium sulfate.
- Example 1 According to the method of Example 1 (a), the reaction between 5-ethyl-3- (1-1-naphthylmethyl) 1-1,3-thiazole-2 (3H) imine and 2- (chlorosulfonol) methyl benzoate was carried out.
- the title compound was synthesized.
- Example 1 (a) tert-butyl ⁇ 2- [2-imino 3- (1-naphthylmethinole)-1,2,3-dihydro-l, 3-thiazo-l-le-5-inole] ethyl ⁇
- the title compound was synthesized by reacting olebamate with methyl 2- (chlorosulfonyl) benzoate.
- the title compound was synthesized according to the methods of Reference Examples 14 and 15. That is, according to the method of Reference Example 14, the reaction of tert-butyl 4- (2-oxoethyl) piperidine-11-carboxylate with 5,5-dibromobarbituric acid was carried out. According to the method, the obtained ⁇ -bromoaldehyde was reacted with thioperia to synthesize the title compound.
- tert-Ptinole 2-[(trifluoroacetyl) amino] -4,5,6,7-tetrahydro-1,3-benzothiazol-6-yl ⁇ Synthesis of olebamate According to the method of Reference Example 1, tert- The title compound was synthesized by the reaction of butyl (2-amino-4,5,6,7-tetrahydro-11,3-benzothiazole-6-yl) capillate with trifluoroacetic anhydride. LCZMS (M + 1, retention time): 36.6.1, 3.53 minutes
- Chymase inhibitory activity (in-vitro test)
- Chymase inhibitory activity IC 5 of the compound of Example No. 1. was 2.1 nM. Industrial applicability
- the compound of the present invention has a chymase inhibitory action, and it is considered that a disease state is considered to be improved based on the action, for example, activation of mast cells, angiotensin II, endothelial cells.
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005511098A JPWO2005000825A1 (ja) | 2003-06-27 | 2004-06-23 | チアゾールイミン類およびオキサゾールイミン類 |
EP04746718A EP1640369A4 (en) | 2003-06-27 | 2004-06-23 | THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND |
US10/561,970 US20070105908A1 (en) | 2003-06-27 | 2004-06-23 | Thiazolimine compound and oxazolimine compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-184321 | 2003-06-27 | ||
JP2003184321 | 2003-06-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005000825A1 true WO2005000825A1 (ja) | 2005-01-06 |
Family
ID=33549607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/009249 WO2005000825A1 (ja) | 2003-06-27 | 2004-06-23 | チアゾールイミン類およびオキサゾールイミン類 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070105908A1 (ja) |
EP (1) | EP1640369A4 (ja) |
JP (1) | JPWO2005000825A1 (ja) |
WO (1) | WO2005000825A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005126428A (ja) * | 2003-09-30 | 2005-05-19 | Takeda Chem Ind Ltd | チアゾリン誘導体およびその用途 |
WO2006051704A1 (ja) * | 2004-11-15 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | イミン化合物 |
JP2007529446A (ja) * | 2004-03-19 | 2007-10-25 | ディファルマ・ソシエタ・ペル・アチオニ | プラミペキソールの製造のための中間体 |
WO2007139230A1 (ja) | 2006-05-31 | 2007-12-06 | Asubio Pharma Co., Ltd. | 7員環化合物並びにその製造法および医薬用途 |
JP2010506928A (ja) * | 2006-10-18 | 2010-03-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チマーゼの新インヒビター |
US7888348B2 (en) | 2004-12-02 | 2011-02-15 | Daiichi Sankyo Company, Limited | 7-membered ring compound and method of production and pharmaceutical application thereof |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2603060A1 (en) | 2005-04-28 | 2006-11-09 | Dainippon Sumitomo Pharma Co., Ltd. | Therapeutic agent for chronic obstructive pulmonary disease |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
WO2007140439A2 (en) | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
WO2008121558A1 (en) | 2007-03-28 | 2008-10-09 | Abbott Laboratories | 1, 3-thiazol-2 (3h) -ylidene compounds as cannabinoid receptor ligands |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP2010527929A (ja) | 2007-05-18 | 2010-08-19 | アボット・ラボラトリーズ | カンナビノイド受容体リガンドとしての新規な化合物 |
US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8859596B2 (en) | 2008-09-16 | 2014-10-14 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
CA2756178A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
EP2518056B1 (en) | 2009-12-25 | 2015-07-29 | Daiichi Sankyo Company, Limited | Seven-membered ring compound and pharmaceutical use therefor |
CN106117161B (zh) * | 2016-06-20 | 2019-07-09 | 中国药科大学 | N-(噻吩-2)酰胺类衍生物在耐吡嗪酰胺结核病及结核病治疗中的医药用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001002665A (ja) * | 1999-06-21 | 2001-01-09 | Taisho Pharmaceut Co Ltd | チアゾリン誘導体 |
JP2001002664A (ja) * | 1999-06-21 | 2001-01-09 | Taisho Pharmaceut Co Ltd | アラニン誘導体 |
JP2001206891A (ja) * | 2000-01-26 | 2001-07-31 | Otsuka Pharmaceut Factory Inc | ホスホン酸ジエステル誘導体 |
WO2002002542A1 (en) * | 2000-06-30 | 2002-01-10 | Sumitomo Pharmaceuticals Company, Limited | Five-membered-ring compound |
JP2003192591A (ja) * | 2001-12-27 | 2003-07-09 | Sumitomo Pharmaceut Co Ltd | 5員環化合物からなる医薬 |
JP2003292485A (ja) * | 2002-04-01 | 2003-10-15 | Yamanouchi Pharmaceut Co Ltd | スルホンアミド誘導体 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU744739B2 (en) * | 1998-02-17 | 2002-02-28 | Nippon Kayaku Kabushiki Kaisha | Novel acetamide derivative and use thereof |
US20050267148A1 (en) * | 1998-07-15 | 2005-12-01 | Teijin Limited | Benzimidazole derivative |
ATE326451T1 (de) * | 1998-08-21 | 2006-06-15 | Daiichi Asubio Pharma Co Ltd | Chinazolin derivate und therapeutische verwendungen davon |
EP1615639A2 (en) * | 2003-04-03 | 2006-01-18 | Semafore Pharmaceuticals, Inc. | Targeted bone marrow protection agents |
-
2004
- 2004-06-23 JP JP2005511098A patent/JPWO2005000825A1/ja not_active Abandoned
- 2004-06-23 US US10/561,970 patent/US20070105908A1/en not_active Abandoned
- 2004-06-23 WO PCT/JP2004/009249 patent/WO2005000825A1/ja not_active Application Discontinuation
- 2004-06-23 EP EP04746718A patent/EP1640369A4/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001002665A (ja) * | 1999-06-21 | 2001-01-09 | Taisho Pharmaceut Co Ltd | チアゾリン誘導体 |
JP2001002664A (ja) * | 1999-06-21 | 2001-01-09 | Taisho Pharmaceut Co Ltd | アラニン誘導体 |
JP2001206891A (ja) * | 2000-01-26 | 2001-07-31 | Otsuka Pharmaceut Factory Inc | ホスホン酸ジエステル誘導体 |
WO2002002542A1 (en) * | 2000-06-30 | 2002-01-10 | Sumitomo Pharmaceuticals Company, Limited | Five-membered-ring compound |
JP2003192591A (ja) * | 2001-12-27 | 2003-07-09 | Sumitomo Pharmaceut Co Ltd | 5員環化合物からなる医薬 |
JP2003292485A (ja) * | 2002-04-01 | 2003-10-15 | Yamanouchi Pharmaceut Co Ltd | スルホンアミド誘導体 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1640369A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005126428A (ja) * | 2003-09-30 | 2005-05-19 | Takeda Chem Ind Ltd | チアゾリン誘導体およびその用途 |
JP2007529446A (ja) * | 2004-03-19 | 2007-10-25 | ディファルマ・ソシエタ・ペル・アチオニ | プラミペキソールの製造のための中間体 |
WO2006051704A1 (ja) * | 2004-11-15 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | イミン化合物 |
US7888348B2 (en) | 2004-12-02 | 2011-02-15 | Daiichi Sankyo Company, Limited | 7-membered ring compound and method of production and pharmaceutical application thereof |
EP2463268A1 (en) | 2004-12-02 | 2012-06-13 | Daiichi Sankyo Company, Limited | Aminomethyl-substituted aromatic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds |
US8507714B2 (en) | 2004-12-02 | 2013-08-13 | Daiichi Sankyo Company, Limited | 7-membered ring compound and method of production and pharmaceutical application thereof |
WO2007139230A1 (ja) | 2006-05-31 | 2007-12-06 | Asubio Pharma Co., Ltd. | 7員環化合物並びにその製造法および医薬用途 |
US8049006B2 (en) | 2006-05-31 | 2011-11-01 | Daiichi Sankyo Company, Limited | 7-membered ring compound and method of production and pharmaceutical application thereof |
JP2010506928A (ja) * | 2006-10-18 | 2010-03-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | チマーゼの新インヒビター |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005000825A1 (ja) | 2006-08-03 |
US20070105908A1 (en) | 2007-05-10 |
EP1640369A1 (en) | 2006-03-29 |
EP1640369A4 (en) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005000825A1 (ja) | チアゾールイミン類およびオキサゾールイミン類 | |
AU2009217356B2 (en) | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | |
JP4906738B2 (ja) | キナーゼインヒビターとして有用な、フェニル置換ピリミジン化合物 | |
JP2022110130A (ja) | 新規の阻害剤 | |
JP2007530589A (ja) | 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用 | |
JP2009522295A (ja) | 置換ビス−アミドメタロプロテアーゼ阻害剤 | |
JP2009503073A (ja) | タンパク質キナーゼ阻害剤としての5−置換チアゾール−2−イルアミノ化合物および組成物 | |
WO2006099735A1 (en) | Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor | |
JP2007523957A (ja) | 新規化学化合物 | |
JP2013199489A (ja) | 新規ピペラジン、医薬組成物、およびその使用方法 | |
EP2468717A1 (en) | Heterocyclic Amide Compounds Useful as Kinase Inhibitors | |
AU2007249891A1 (en) | Selective inhibitors of ROCK protein kinase and uses thereof | |
WO2001055123A1 (fr) | Composes cycliques a 5 chainons, contenant de l'azote, et medicaments contenant ces composes comme ingredients actifs | |
WO2018039518A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
JPWO2004007464A1 (ja) | イミダゾール誘導体 | |
WO1998000420A1 (fr) | Nouveaux derives de thiophene et compositions medicamenteuses les contenant | |
CA2946754A1 (en) | Optically active pde10 inhibitor | |
CA2166165A1 (en) | Substituted 4-phenylthiazole derivatives, process for their preparation and pharmaceutical compositions containing them | |
US20080207683A1 (en) | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s | |
ES2911049T3 (es) | Antagonistas heterocíclicos de P2X7 | |
JP2007517832A (ja) | Srcファミリータンパク質キナーゼの阻害剤としての5員環の複素環式化合物 | |
JP5760005B2 (ja) | 新規(複素環/テトラヒドロピリジン)−(ピペラジニル)−1−アルカノンおよび(複素環/ジヒドロピロリジン)−(ピペラジニル)−1−アルカノン誘導体、並びにp75阻害剤としてのこれらの使用 | |
JP2021525792A (ja) | ベンズイミダゾール化合物、及びアルツハイマー病又はハンチントン病の治療のためのその使用 | |
WO2008053861A1 (fr) | Nouveau composé ayant un squelette 1,4-benzoxazin-3-one | |
WO2024017897A1 (en) | 1,3,4-oxadiazole derivatives as selective histone deacetylase 6 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005511098 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007105908 Country of ref document: US Ref document number: 10561970 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004746718 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004746718 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10561970 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004746718 Country of ref document: EP |